Aruna Mani

1.5k citations
31 papers · 1.0k · h-index 15

Impact in

  • Oncology top 5%
    • HER2/EGFR in Cancer Research
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Cancer Treatment and Pharmacology
  • Immunology top 10%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction

Papers in

Co-authors
William E. Carson (5 shared papers)Sung‐Bae Kim (6 shared papers)Cristina Saura (6 shared papers)Julie M. Roda (4 shared papers)Monika Patre (3 shared papers)Sherene Loi (3 shared papers)Francisco J. Esteva (3 shared papers)Michelino De Laurentiis (3 shared papers)
Journals
Cancer Research (8 papers)Breast Cancer Research and Treatment (4 papers)Annals of Oncology (3 papers)Journal of Clinical Oncology (3 papers)The Journal of Immunology (2 papers)
Partner nations
United StatesSpainUnited Kingdom

In The Last Decade

Aruna Mani

30 papers receiving 1.0k citations

Peers

Aruna Mani
Comparison fields: 5 of 59
  • Oncology 657
  • Immunology 297
  • Radiology, Nuclear Medicine and Imaging 191
  • Cancer Research 117
  • Pulmonary and Respiratory Medicine 222
Replace Abraham C.F. Leung with:
Abraham C.F. Leung United States
Debora Pezzuolo Italy
France Blanchard France
Gilles Gallant United States
Spencer D. Martin Canada
Noah Goodman United States
Kristine Rinn United States
Jasmine I. Rizzo United States
Charlotte Lemech Australia
Marissa S. Mattar United States
Aruna Mani relative to Abraham C.F. Leung United States Abraham C.F. Leung's profile →
Citations per field
00.5×2×2.6×
Abraham C.F. Leung · 1×
Citations per year

Countries citing papers authored by Aruna Mani

Since Specialization
Citations

This map shows the geographic impact of Aruna Mani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aruna Mani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aruna Mani more than expected).

Fields of papers citing papers by Aruna Mani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aruna Mani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aruna Mani. The network helps show where Aruna Mani may publish in the future.

Co-authors

The 25 scholars most cited alongside Aruna Mani, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aruna Mani Line = papers co-authored together Aruna Mani links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
The Lancet Oncology ·Leisha A. Emens, Francisco J. Esteva, Mark Beresford, Cristina Saura, Michelino De Laurentiis, Sung‐Bae Kim, Seock‐Ah Im, Yifan Wang, Roberto Salgado, Aruna Mani, Jigna Shah, Chiara Lambertini, Haiying Liu, Sanne Lysbet de Haas, Monika Patre, Sherene Loi
2020296
2
Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets
The Journal of Immunology ·Julie M. Roda, Robin Parihar, Amy Lehman, Aruna Mani, Susheela Tridandapani, William E. Carson
2006107
3
IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-γ Production
The Journal of Immunology ·Alena Cristina Jaime‐Ramirez, Bethany L. Mundy-Bosse, SriVidya Kondadasula, Natalie Jones, Julie M. Roda, Aruna Mani, Robin Parihar, Volodymyr Karpa, Tracey L. Papenfuss, Krista LaPerle, Elizabeth Biller, Amy Lehman, Abhik Ray Chaudhury, David Jarjoura, Richard W. Burry, William E. Carson
201187
4
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
Breast Cancer Research and Treatment ·Nicholas C. Turner, Rebecca Dent, Joyce O’Shaughnessy, Sung‐Bae Kim, Steven J. Isakoff, Carlos H. Barrios, Shigehira Saji, Igor Bondarenko, Zbigniew Nowecki, Qinshu Lian, Sarah-Jayne Reilly, Heather Hinton, Matthew Wongchenko, Bruno Kovic, Aruna Mani, Mafalda Oliveira
202169
5
Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
Journal of Clinical Oncology ·Pravin T. P. Kaumaya, Kevin Foy, Joan T. Garrett, Sharad Rawale, Daniele Vicari, Jennifer M. Thurmond, Tammy Lamb, Aruna Mani, Y Kane, Catherine Balint, Donald Chalupa, Gregory A. Otterson, Charles L. Shapiro, Jeffrey M. Fowler, Michael R. Grever, Tanios Bekaii‐Saab, William E. Carson
200969
6
Apoptosis of Multiple Myeloma
International Journal of Hematology ·Marcela Oancea, Aruna Mani, Mohamad A. Hussein, Alexandru Almasan
200447
7
Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
Annals of Oncology ·Leisha A. Emens, Francisco J. Esteva, Mark Beresford, Cristina Saura, Michelino De Laurentiis, S.-B. Kim, S.-A. Im, Y. Wang, Aruna Mani, Jigna Shah, H. Liu, Sanne de Haas, Monika Patre, Sherene Loi
201947
8
Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)
Cancer Research ·Peter Schmid, Delphine Loirat, Peter Savas, Enrique Espinosa, Valentina Boni, Antoîne Italiano, Shane White, Stina Mui Singel, Nimali P. Withana, Aruna Mani, Suwen Li, Adam Harris, Matthew Wongchenko, Marie Paule Sablin
201943
9
Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
Cancer Research ·LA Emens, Francisco J. Esteva, M Beresford, Cristina Saura, Michelino De Laurentiis, S-B. Kim, S-A. Im, Monika Patre, Yibin Wang, Aruna Mani, Hui Liu, Sanne de Haas, Sherene Loi
201940
10
Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature
Breast Cancer Research and Treatment ·Simon B. Zeichner, Stuart Herna, Aruna Mani, Tadeu Ambros, Alberto J. Montero, Reshma Mahtani, Eugene R. Ahn, Charles L. Vogel
201537
11
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
Breast Cancer Research and Treatment ·Aruna Mani, Julie M. Roda, Donn C. Young, Michael A. Caligiuri, Gini F. Fleming, Peter A. Kaufman, Adam Brufsky, Susan Ottman, William E. Carson, Charles L. Shapiro
200836
12
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)
Therapeutic Advances in Medical Oncology ·Sara A. Hurvitz, Rashi Singh, Brad Adams, Julie Taguchi, David W. Chan, Robert Dichmann, Aurelio Castrellon, Eddie Hu, Jonathan Berkowitz, Aruna Mani, Brian DiCarlo, Rena D. Callahan, Ira Smalberg, Xiaoyan Wang, Ivana Meglar, Diego Martinez, Evthokia Hobbs, Dennis J. Slamon
201827
13
Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A
Cancer Research ·Rebecca Dent, Sung‐Bae Kim, Mafalda Oliveira, Carlos H. Barrios, Joyce O’Shaughnessy, Steven J. Isakoff, Shigehira Saji, Ruffo Freitas‐Júnior, M. Philco, Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew Wongchenko, Aruna Mani, Nicholas C. Turner
202123
14
IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC).
Journal of Clinical Oncology ·Rebecca Dent, Sung‐Bae Kim, Mafalda Oliveira, Steven J. Isakoff, Carlos H. Barrios, Joyce O’Shaughnessy, Xuyang Lu, Matthew Wongchenko, Denise Bradley, Aruna Mani, José Baselga, Nicholas C. Turner
201820
15
Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse
Breast Cancer Basic and Clinical Research ·Simon B. Zeichner, Tadeu Ambros, John Zaravinos, Alberto J. Montero, Reshma Mahtani, Eugene R. Ahn, Aruna Mani, Nathan Markward, Charles L. Vogel
201518
16
Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer
JCO Precision Oncology ·Matthew Wongchenko, Sung‐Bae Kim, Cristina Saura, Mafalda Oliveira, Doron Lipson, Mark Kennedy, Mandy Greene, Virginia Breese, Aruna Mani, Na Xu, Rebecca Dent
202014
17
139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Annals of Oncology ·Rebecca Dent, Mafalda Oliveira, Steven J. Isakoff, S-A. Im, Marc Espié, Sibel Blau, Antoinette R. Tan, Cristina Saura, Matthew Wongchenko, N. Xu, Denise Bradley, S-J. Reilly, Aruna Mani, S-B. Kim
202014
18
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer
Breast Cancer Research and Treatment ·Tadeu Ambros, Simon B. Zeichner, John Zaravinos, Alberto J. Montero, Eugene R. Ahn, Aruna Mani, Lori Kronish, Reshma Mahtani, Charles L. Vogel
201414
19
283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial
Annals of Oncology ·Nicholas C. Turner, Rebecca Dent, Joyce O’Shaughnessy, S-B. Kim, Steven J. Isakoff, C.H. Barrios, Shigehira Saji, Igor Bondarenko, Zbigniew Nowecki, Qinshu Lian, S-J. Reilly, Heather Hinton, Matthew Wongchenko, Aruna Mani, Mafalda Oliveira
202010
20
Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.
PubMed ·R Massari, Martina Barone, Romina Basilico, Consiglia Carella, Antonella Colasante, De Tursi M, Alessio Filippone, Luigi Guetti, Aruna Mani
20149

About Aruna Mani

Aruna Mani is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 31 papers that have together received 1.0k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (12 papers), Cancer Treatment and Pharmacology (11 papers), HER2/EGFR in Cancer Research (9 papers), Breast Cancer Treatment Studies (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Immune Cell Function and Interaction (3 papers). The work is most often cited by research in Oncology (657 citations), Immunology (297 citations), Radiology, Nuclear Medicine and Imaging (191 citations), Cancer Research (117 citations) and Pulmonary and Respiratory Medicine (222 citations). Aruna Mani has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include William E. Carson, Sung‐Bae Kim, Cristina Saura, Julie M. Roda, Monika Patre, Sherene Loi, Francisco J. Esteva, Michelino De Laurentiis, Robin Parihar and Amy Lehman. Their work appears in journals such as Cancer Research, Breast Cancer Research and Treatment, Annals of Oncology, Journal of Clinical Oncology and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Abraham C.F. LeungBreakdown of academic impact, for papers by Debora PezzuoloBreakdown of academic impact, for papers by France BlanchardBreakdown of academic impact, for papers by Gilles GallantBreakdown of academic impact, for papers by Spencer D. MartinBreakdown of academic impact, for papers by Noah GoodmanBreakdown of academic impact, for papers by Kristine RinnBreakdown of academic impact, for papers by Jasmine I. RizzoBreakdown of academic impact, for papers by Charlotte LemechBreakdown of academic impact, for papers by Marissa S. Mattar